BL LATANOPROST SOLUTION

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

LATANOPROST

Verfügbar ab:

BAUSCH & LOMB INC

ATC-Code:

S01EE01

INN (Internationale Bezeichnung):

LATANOPROST

Dosierung:

50MCG

Darreichungsform:

SOLUTION

Zusammensetzung:

LATANOPROST 50MCG

Verabreichungsweg:

OPHTHALMIC

Einheiten im Paket:

2.5ML

Verschreibungstyp:

Prescription

Therapiebereich:

PROSTAGLANDIN ANALOGS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0132916002; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2013-04-02

Fachinformation

PRODUCT MONOGRAPH
PR
BL LATANOPROST
Latanoprost Ophthalmic Solution
50 mcg/mL
PROSTAGLANDIN F2Α ANALOGUE
BAUSCH & LOMB INCORPORATED DATE OF REVISION:
1400 North Goodman Street
June 30, 2022
Rochester NY, USA
14609
Imported and Distributed by:
BAUSCH + LOMB CORPORATION
520 Applewood Crescent
Vaughan, Ontario
L4K 4B4
Control #: 260462
_Pr_
_BL LATANOPROST Product Monograph _
_Page 2 of 28_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION..............................................................................
3
INDICATIONS
AND
CLINICAL
USE
...................................................................................
3
CONTRAINDICATIONS.......................................................................................................
3
WARNINGS
AND
PRECAUTIONS
......................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................
6
DRUG
INTERACTIONS
.......................................................................................................
7
DOSAGE
AND
ADMINISTRATION
.....................................................................................
7
OVERDOSAGE.....................................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY
.................................................................... 9
STORAGE
AND
STABILITY
...............................................................................................10
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING .....................................................10
PART II: SCIENTIFIC INFORMATION
.............................................................................
11
PHARMACEUTICAL
INFORMATION................................................................................11
CLINICAL
TRIALS
.........................